Coronary Syndromes Articles & Analysis
9 news found
The frequency of net-clinical benefit events - a composite of stroke or systemic embolism, major bleeding, myocardial infarction, acute coronary syndrome, or cardiovascular death - was 13.8 per 100 patient years in the rivaroxaban and 13.6 in the VKA group (95% CI 0.72 to 1.31, HR=0.97). ...
ByBayer AG
About PAD Cardiovascular diseases (CVD), including coronary artery disease (CAD) and peripheral artery disease (PAD), account for around 1 in every 3 deaths worldwide. ...
ByBayer AG
Giulio Guagliumi from ASST Papa Giovanni XXIII in Bergamo, Italy discusses the “use of IVUS+NIRS imaging for decision making in acute coronary syndrome,” during the 2020 EuroPCR e-course. The course discusses: The frequency of culprit lesion ambiguity in ACS The value of IVUS+NIRS imaging in challenging scenarios Integrating the information ...
Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including MDD, Schizophrenia, Migraine, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome (ACS), Obesity and ...
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
ByBayer AG
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued guidelines will be a catalyst for non-invasive image, revolutionizing the way patients with coronary artery disease are diagnosed and treated. In a highly anticipated document published online yesterday in Circulation and ...
ByElucid
Taylor, Chief of the Division of Cardiac Surgery and Director of Coronary Revascularization and site Principal Investigator at the University of Maryland Medical Center. ...
With Revacept severe complications such as heart attacks and stroke in combination with bleedings were rarer than with the standard therapy Aspirin and Clopidogrel in patients with coronary artery disease. Revacept seals the lesion in a blood vessel like a plaster. ...
“We are enthusiastic about studying the novel DynamX device, which is the first metallic device treating coronary artery disease that has been shown to restore pulsatility and positive adaptive remodeling of coronary arteries. ...